Ariad’s Iclusig Clinical Program Held Up By Mounting Cardio Events
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA issued a partial clinical hold due to the growing number of cardiovascular events in the pivotal PACE trial, which had been ongoing after ponatinib won accelerated approval based on response rate in December 2012.